Nanirx, Inc.
Records under this name other than patents Nanirx, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Nanirx, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,927,580 | Tat-based immunomodulatory compositions and methods of their discovery and use Formerly held Term ended Term ended Jul 7, 2026 · From the USPTO record | Term ended | Term ended Jul 7, 2026 | From the USPTO record |
| US 9,206,239 | Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides Formerly held Lapsed on the fee record Ended Dec 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 8, 2023 | From the USPTO record |
| US 8,530,431 | Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides Formerly held Lapsed on the fee record Ended Sep 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 10, 2021 | From the USPTO record |
| US 6,667,151 | Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease Formerly held Term ended Term ended Aug 10, 2020 · From the USPTO record | Term ended | Term ended Aug 10, 2020 | From the USPTO record |
| US 8,323,928 | Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease Formerly held Term ended Term ended Aug 10, 2020 · From the USPTO record | Term ended | Term ended Aug 10, 2020 | From the USPTO record |